Lacosamida Zentiva (Lacosamide)

Lacosamide selectively enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilises hyper‑excitable neurons and reduces the ability of abnormal rapid firing to spread, thereby decreasing seizure activity.

The dose of lacosamide is individualized by the prescribing clinician based on the patient’s age, renal function, concomitant therapies and seizure control needs. The prescriber determines the appropriate starting dose and any titration schedule.

Safety of lacosamide in pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide’s mechanism—enhancing slow sodium‑channel inactivation—differs from many older agents that target fast inactivation. Compared with drugs such as carbamazepine, lacosamide may have a lower risk of certain drug‑enzyme interactions and offers an alternative for patients who do not respond adequately to traditional sodium‑channel blockers.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat and direct light. Do not store in a refrigerator or freezer.

Lacosamida Zentiva is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious adverse events include suicidal ideation or behaviour, severe skin reactions such as Stevens‑Johnson syndrome, and cardiac conduction abnormalities like PR‑interval prolongation. Patients should be monitored for these events, and any concerning symptoms should be reported to a healthcare professional promptly.

Patients with known hypersensitivity to lacosamide or any excipients in the tablet should avoid the product. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, or those taking interacting medications that could compromise safety.